Table 3.

The results of association analysis between relative expressions of genes in tumoral tissues compared with ANCTs and patients’ clinicopathological data (up/downregulation of genes was defined based on relative expression of each gene in tumoral tissue compared with the paired ANCT)

	IFNG upregulation	IFNG downregulation	P value	IFNG-AS1 upregulation	IFNG-AS1 downregulation	P value
Age			0.63			0.5
< 40	8 (67.6%)	3 (27.3%)		9 (81.8%)	2 (18.2%)
40–50	10 (58.2%)	7 (41.2%)		11 (64.7%)	6 (35.3%)
51–60	10 (76.9%)	3 (23.1%)		10 (76.9%)	3 (23.1%)
61–70	5 (62.5%)	3 (37.5%)		5 (62.5%)	3 (37.5%)
> 71	2 (40%)	3 (60%)		2 (40%)	3 (60%)
Stage			0.95			0.25
1	9 (56.3%)	7 (43.7%)		10 (62.5%)	6 (37.5%)
2	10 (66.7%)	5 (33.3%)		9 (60%)	6 (40%)
3	11 (68.8%)	5 (31.2%)		14 (87.5%)	2 (12.5%)
4	4 (80%)	1 (20%)		3 (20%)	2 (80%)
Histological grade			0.87			0.91
1	5 (62.5%)	3 (37.5%)		6 (75%)	2 (25%)
2	16 (69.6%)	7 (30.4%)		15 (62.5%)	8 (34.8%)
3	10 (62.5%)	6 (37.5%)		12 (75%)	4 (25%)
Mitotic rate			0.9			0.64
1	13 (68.4%)	6 (31.6%)		14 (73.7%)	5 (26.3%)
2	11 (61.1%)	7 (38.9%)		11 (61.1%)	7 (38.9%)
3	3 (60%)	2 (40%)		4 (80%)	1 (20%)
Tumor size			0.7			0.67
< 2	9 (56.3%)	7 (43.7%)		12 (75%)	4 (25%)
2–5	22 (66.7%)	11 (33.3%)		21 (63.6%)	12 (36.4%)
> 5	1 (100%)	0 (0%)		1 (100%)	0 (0%)
ER status			0.08			0.65
Positive	26 (60.5%)	17 (39.5%)		29 (67.4%)	14 (32.6%)
Negative	6 (100%)	0 (0%)		5 (16.7%)	1 (83.3%)
PR status			0.07			0.46
Positive	22 (59.5%)	15 (40.5%)		25 (67.6%)	12 (32.4%)
Negative	10 (90.9%)	1 (9.1%)		9 (81.8%)	2 (18.2%)
HER2 status			0.48			0.27
Positive	7 (58.3%)	5 (41.7%)		7 (58.3%)	5 (41.7%)
Negative	25 (69.4%)	11 (30.6%)		27 (75%)	9 (25%)